HRP20231065T1 - Postupci koji uključuju alvelestat inhibitor neutrofilne elastaze za liječenje respiratorne bolesti posredovane putem nedostatka alfa-1 antitripsina - Google Patents
Postupci koji uključuju alvelestat inhibitor neutrofilne elastaze za liječenje respiratorne bolesti posredovane putem nedostatka alfa-1 antitripsina Download PDFInfo
- Publication number
- HRP20231065T1 HRP20231065T1 HRP20231065TT HRP20231065T HRP20231065T1 HR P20231065 T1 HRP20231065 T1 HR P20231065T1 HR P20231065T T HRP20231065T T HR P20231065TT HR P20231065 T HRP20231065 T HR P20231065T HR P20231065 T1 HRP20231065 T1 HR P20231065T1
- Authority
- HR
- Croatia
- Prior art keywords
- salt
- alvelestat
- disease
- administration
- day
- Prior art date
Links
- QNQZWEGMKJBHEM-UHFFFAOYSA-N 6-methyl-5-(2-methylpyrazol-3-yl)-n-[(5-methylsulfonylpyridin-2-yl)methyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound O=C1N(C=2C=C(C=CC=2)C(F)(F)F)C(C)=C(C=2N(N=CC=2)C)C=C1C(=O)NCC1=CC=C(S(C)(=O)=O)C=N1 QNQZWEGMKJBHEM-UHFFFAOYSA-N 0.000 title claims 25
- 229950005666 alvelestat Drugs 0.000 title claims 25
- 238000000034 method Methods 0.000 title claims 7
- 230000001404 mediated effect Effects 0.000 title claims 4
- 102000002255 Secretory Proteinase Inhibitory Proteins Human genes 0.000 title 1
- 108010000303 Secretory Proteinase Inhibitory Proteins Proteins 0.000 title 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 title 1
- 239000003591 leukocyte elastase inhibitor Substances 0.000 title 1
- 208000023504 respiratory system disease Diseases 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 26
- 201000010099 disease Diseases 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims 9
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims 9
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims 9
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 4
- 206010014561 Emphysema Diseases 0.000 claims 4
- 208000006673 asthma Diseases 0.000 claims 4
- 201000009267 bronchiectasis Diseases 0.000 claims 4
- 230000007812 deficiency Effects 0.000 claims 3
- 210000002345 respiratory system Anatomy 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 125000005490 tosylate group Chemical class 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Claims (11)
1. Alvelestat ili njegova sol, naznačen time, da je za uporabu u postupku za liječenje bolesti respiratornog sustava koja je posredovana nedostatkom α-1 antitripsina, gdje se bolest bira od kronične opstrukcijske plućne bolesti (KOPB), emfizema, astme i bronhiektazija, kod pacijenta kojemu je to potrebno i koji nije imao odgovor na prethodnu terapiju alfa-1 antitripsinom (AAT), pri čemu postupak obuhvaća davanje pacijentu učinkovite količine alvelestata ili njegove soli, i pritom količina alvelestata ili njegove soli koja se daje iznosi 120-300 mg dva puta dnevno.
2. Alvelestat ili njegova sol, naznačen time, da je za uporabu u postupku za liječenje bolesti respiratornog sustava koja je posredovana nedostatkom α-1 antitripsina, gdje se bolest bira od kronične opstrukcijske plućne bolesti (KOPB), emfizema, astme i bronhiektazija, kod pacijenta kojemu je to potrebno i koji nije imao odgovor na prethodnu terapiju alfa-1 antitripsinom (AAT), pri čemu postupak obuhvaća davanje pacijentu učinkovite količine alvelestata ili njegove soli, kao i davanje alvelestata ili njegove soli u eskalirajućem režimu za doziranje, te obuhvaća:
- davanje alvelestata ili njegove soli u dozi od 60 mg dva puta dnevno u prvom vremenskom periodu,
- davanje alvelestata ili njegove soli u dozi od 120 mg dva puta dnevno nakon toga,
pri čemu prvi vremenski period iznosi 5-20 dana, poželjno oko jednog tjedna (7 dana).
3. Alvelestat ili njegova sol, naznačen time, da je za uporabu u postupku za liječenje bolesti respiratornog sustava koja je posredovana nedostatkom α-1 antitripsina, gdje se bolest bira od kronične opstrukcijske plućne bolesti (KOPB), emfizema, astme i bronhiektazija, kod pacijenta kojemu je to potrebno i koji nije imao odgovor na prethodnu terapiju alfa-1 antitripsinom (AAT), pri čemu postupak obuhvaća davanje pacijentu učinkovite količine alvelestata ili njegove soli, kao i davanje alvelestata ili njegove soli u eskalirajućem režimu za doziranje, te obuhvaća:
- davanje alvelestata ili njegove soli u dozi od 60 mg dva puta dnevno u prvom vremenskom periodu,
- davanje alvelestata ili njegove soli u dozi od 120 mg dva puta dnevno u drugom vremenskom periodu,
- davanje alvelestata ili njegove soli u dozi od 180 mg dva puta dnevno u trećem vremenskom periodu, i
- davanje alvelestata ili njegove soli u dozi od 240 mg dva puta dnevno nakon toga,
pri čemu prvi, drugi i treći vremenski period iznose 5-20 dana, poželjno oko jednog tjedna (7 dana).
4. Alvelestat ili njegova sol za uporabu prema patentnom zahtjevu 1, naznačen time, da količina alvelestata ili njegove soli koja se određuje, iznosi 220-300 mg dva puta dnevno.
5. Alvelestat ili njegova sol za uporabu prema patentnom zahtjevu 1, naznačen time, da se određuje davanje 120 mg alvelestata ili njegove soli po davanju.
6. Alvelestat ili njegova sol za uporabu prema patentnom zahtjevu 1, naznačen time, da se određuje davanje 240 mg alvelestata ili njegove soli po davanju.
7. Alvelestat ili njegova sol za uporabu prema bilo kojem od patentnih zahtjeva 1 do 6, naznačen time, da bolest je KOPB.
8. Alvelestat ili njegova sol za uporabu prema bilo kojem od patentnih zahtjeva 1 do 6, naznačen time, da bolest je emfizem.
9. Alvelestat ili njegova sol za uporabu prema bilo kojem od patentnih zahtjeva 1 do 6, naznačen time, da bolest je astma.
10. Alvelestat ili njegova sol za uporabu prema bilo kojem od patentnih zahtjeva 1 do 6, naznačen time, da bolest su bronhiektazije.
11. Alvelestat ili njegova sol za uporabu prema bilo kojem od patentnih zahtjeva 1 do 10, naznačen time, da aktivni sastojak sadrži tosilatnu sol alvelestata ili se sastoji od tosilatne soli alvelestata.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2005520.8A GB202005520D0 (en) | 2020-04-16 | 2020-04-16 | Elastase inhibition |
| GBGB2005519.0A GB202005519D0 (en) | 2020-04-16 | 2020-04-16 | Elastase inhibition |
| US202062706195P | 2020-08-04 | 2020-08-04 | |
| PCT/GB2021/050653 WO2021209739A1 (en) | 2020-04-16 | 2021-03-16 | Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency |
| EP21714345.2A EP4106757B1 (en) | 2020-04-16 | 2021-03-16 | Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231065T1 true HRP20231065T1 (hr) | 2023-12-22 |
Family
ID=78083570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231065TT HRP20231065T1 (hr) | 2020-04-16 | 2021-03-16 | Postupci koji uključuju alvelestat inhibitor neutrofilne elastaze za liječenje respiratorne bolesti posredovane putem nedostatka alfa-1 antitripsina |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20230190723A1 (hr) |
| EP (2) | EP4106757B1 (hr) |
| JP (1) | JP2023522010A (hr) |
| AU (1) | AU2021256835A1 (hr) |
| DK (1) | DK4106757T3 (hr) |
| ES (1) | ES2962498T3 (hr) |
| FI (1) | FI4106757T3 (hr) |
| HR (1) | HRP20231065T1 (hr) |
| HU (1) | HUE064089T2 (hr) |
| IL (1) | IL297211A (hr) |
| LT (1) | LT4106757T (hr) |
| MX (1) | MX2022012942A (hr) |
| PL (1) | PL4106757T3 (hr) |
| PT (1) | PT4106757T (hr) |
| SI (1) | SI4106757T1 (hr) |
| WO (2) | WO2021209740A1 (hr) |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5674708A (en) | 1989-06-23 | 1997-10-07 | Trustees Of The University Of Pennsylvania | α-1-antichymotrypsin analogues having elastase inhibitory activity |
| CA2105304C (en) | 1991-03-01 | 2005-10-04 | Arthur C. Ley | Inhibitors of human neutrophil elastase and human cathepsin g |
| WO1992020357A1 (en) | 1991-05-23 | 1992-11-26 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of cathepsin g and elastase for preventing connective tissue degradation |
| US5216022A (en) | 1991-12-19 | 1993-06-01 | Cortech, Inc. | Aromatic esters of phenylenedialkanoates as inhibitors of human neutrophil elastase |
| CA2133658A1 (en) | 1992-04-16 | 1993-10-28 | Peter R. Bernstein | Heterocyclic derivatives |
| WO1993021214A1 (en) | 1992-04-16 | 1993-10-28 | Zeneca Limited | Alpha-aminoboronic acid peptides and their use as elastase inhibitors |
| US5441960A (en) | 1992-04-16 | 1995-08-15 | Zeneca Limited | 1-pyrimidinylacetamide human leukocyte elastate inhibitors |
| US5486529A (en) | 1992-04-16 | 1996-01-23 | Zeneca Limited | Certain pyridyl ketones for treating diseases involving leukocyte elastase |
| GB9307555D0 (en) | 1992-04-16 | 1993-06-02 | Zeneca Ltd | Heterocyclic compounds |
| GB9211783D0 (en) | 1992-06-04 | 1992-07-15 | Ici Plc | Amide derivatives |
| GB9214053D0 (en) | 1992-07-02 | 1992-08-12 | Ici Plc | Heterocyclic amides |
| GB9402680D0 (en) | 1994-02-11 | 1994-04-06 | Zeneca Ltd | Pyrrolidine derivatives |
| EP0763055B1 (en) | 1994-06-02 | 1999-11-03 | Merrell Pharmaceuticals Inc. | Perfluoroalkyl ketone inhibitors of elastase and processes for making the same |
| ATE246708T1 (de) | 1994-06-02 | 2003-08-15 | Aventis Pharma Inc | Elatase-inhibitoren |
| US5618792A (en) | 1994-11-21 | 1997-04-08 | Cortech, Inc. | Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase |
| GB9502152D0 (en) | 1995-02-03 | 1995-03-29 | Zeneca Ltd | Proline derivatives |
| AR006401A1 (es) | 1996-03-28 | 1999-08-25 | Glaxo Group Ltd | Compuestos de pirrolopirrolona, una composicion farmaceutica que los contiene, su uso en la fabricacion de un medicamento y en terapia, procesospara su preparación y compuestos intermediarios para dichos procesos. |
| ATE297466T1 (de) | 1996-04-12 | 2005-06-15 | American Nat Red Cross | Mutierter plasminogen-aktivator-inhibitor typ 1 und seine verwendungen |
| GB9719187D0 (en) | 1997-09-09 | 1997-11-12 | Glaxo Group Ltd | Compounds |
| PE107899A1 (es) | 1997-09-09 | 1999-11-17 | Glaxo Group Ltd | Derivados de pirrolopirrolona como inhibidores de elastasa leucocitaria |
| KR20010078724A (ko) | 1998-06-03 | 2001-08-21 | 존 더블류. 갈루치 2세 | 세린 프로테아제 저해제로서의 인돌 및테트라히드로이소퀴놀린을 함유하는 α-케토 옥사디아졸 |
| WO1999062538A1 (en) | 1998-06-03 | 1999-12-09 | Cortech Inc. | Alpha-keto oxadiazoles as serine protease inhibitors |
| US20030069187A1 (en) | 2001-10-05 | 2003-04-10 | Rao Srinivasa K. | Elastase inhibitors |
| US20030119073A1 (en) | 2001-12-21 | 2003-06-26 | Stephen Quirk | Sensors and methods of detection for proteinase enzymes |
| GB0219896D0 (en) | 2002-08-27 | 2002-10-02 | Bayer Ag | Dihydropyridine derivatives |
| TW200500341A (en) | 2002-11-12 | 2005-01-01 | Astrazeneca Ab | Novel compounds |
| SE0302324D0 (sv) | 2003-08-28 | 2003-08-28 | Astrazeneca Ab | Novel compounds |
| SE0302323D0 (sv) | 2003-08-28 | 2003-08-28 | Astrazeneca Ab | Novel compounds |
| SE0302486D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| SE0302487D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| JP4825194B2 (ja) | 2004-02-26 | 2011-11-30 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | １，４−ジアリール−ジヒドロピリミジン−２−オン化合物およびヒト好中球エラスターゼ阻害剤としてのそれらの使用 |
| WO2005082863A2 (en) | 2004-02-26 | 2005-09-09 | Bayer Healthcare Ag | 1,4 diaryl-dihydropyrimidin-2 ones and their use as a human neutrophil elastase inhibitors |
| WO2006070012A1 (en) | 2004-12-30 | 2006-07-06 | Ingenium Pharmaceuticals Ag | Agents useful in treating inflammatory bowel disease |
| GB0502258D0 (en) | 2005-02-03 | 2005-03-09 | Argenta Discovery Ltd | Compounds and their use |
| TW200700392A (en) | 2005-03-16 | 2007-01-01 | Astrazeneca Ab | Novel compounds |
| GB0512940D0 (en) | 2005-06-24 | 2005-08-03 | Argenta Discovery Ltd | Compounds and their use |
| GB0605469D0 (en) | 2006-03-17 | 2006-04-26 | Argenta Discovery Ltd | Multimers of heterocyclic compounds and their use |
| WO2009013444A1 (en) | 2007-07-25 | 2009-01-29 | Argenta Discovery Limited | Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors |
| AU2007246889B2 (en) | 2006-05-04 | 2011-03-10 | Chiesi Farmaceutici S.P.A. | Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors |
| TW200808763A (en) | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds I |
| TW200808771A (en) | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds II |
| RU2419625C2 (ru) | 2006-05-23 | 2011-05-27 | Айрм Ллк | Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы |
| WO2007137080A2 (en) | 2006-05-23 | 2007-11-29 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
| ES2293832B1 (es) | 2006-07-17 | 2009-05-04 | Cargoflet S.A. | Sistema de transporte masivo de gas natural a alta presion por via maritima. |
| US20110003858A1 (en) | 2006-09-04 | 2011-01-06 | Bergstroem Lena | Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors |
| BRPI0716897A2 (pt) | 2006-09-21 | 2013-10-22 | Activx Biosciences Inc | Composto ou um derivado farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para inibir uma ação de uma serina hidrolase e para tratamento de uma doença mediada por serina hidrolase, e, artigo de fabricação. |
| ATE493174T1 (de) | 2007-01-10 | 2011-01-15 | Irm Llc | Verbindungen und zusammensetzungen als kanal- aktivierende proteasehemmer |
| JP2010518099A (ja) | 2007-02-09 | 2010-05-27 | アイアールエム・リミテッド・ライアビリティ・カンパニー | チャネル活性化プロテアーゼ阻害剤としての化合物および組成物 |
| WO2008104752A1 (en) | 2007-02-26 | 2008-09-04 | Astrazeneca Ab | Dihydropyridones as elastase inhibitors |
| WO2009037413A1 (en) | 2007-09-19 | 2009-03-26 | Argenta Discovery Limited | Dimers of 5- [ (4-cyanophenyl) sulfinyl] -6-methyl-2-oxo-1- [3- (trifluoromethyl)phenyl] -1,2-dihydropyridine-3-carboxamide as inhibitors of human neutrophil elastase for treating respiratory diseases |
| WO2009058076A1 (en) | 2007-11-02 | 2009-05-07 | Astrazeneca Ab | 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase |
| TW200924770A (en) | 2007-11-06 | 2009-06-16 | Astrazeneca Ab | Novel compounds 089 |
| WO2009060206A1 (en) | 2007-11-07 | 2009-05-14 | Argenta Discovery Limited | 3,4,6,7-tetrahydro-1h-pyrrolo[3,4-d]pyrimidine-2,5-diones and their therapeutic use |
| WO2009060158A1 (en) | 2007-11-07 | 2009-05-14 | Argenta Discovery Limited | 4- (4-cyanophenyl) -1- (3-trifluoromethylphenyl) -3,4, 6, 7-tetrahydro-1h-pyrrolo [3, 4- d] pyrimidine-2, 5-dione derivatives and their use as human neutrophil elastase inhibitors |
| GB0817429D0 (en) | 2008-09-23 | 2008-10-29 | Argenta Discovery Ltd | Enzyme inhibitors |
| TW201036957A (en) | 2009-02-20 | 2010-10-16 | Astrazeneca Ab | Novel salt 628 |
| BR112012007322A2 (pt) | 2009-10-02 | 2017-06-06 | Astrazeneca Ab | composto de 2-piridona usados como inibidores de neutrófilo elastase |
| US20110212181A1 (en) | 2010-02-26 | 2011-09-01 | The University Of Hong Kong | Compositions and methods for treating chronic respiratory inflammation |
| WO2011110852A1 (en) | 2010-03-10 | 2011-09-15 | Astrazeneca Ab | Polymorphic forms of 6- [2- (4 -cyanophenyl) - 2h - pyrazol - 3 - yl] - 5 -methyl - 3 - oxo - 4 - (trifluoromethyl - phenyl) 3,4-dihydropyrazine-2-carboxylic acid ethylamide |
| GB201004178D0 (en) | 2010-03-12 | 2010-04-28 | Pulmagen Therapeutics Inflamma | Enzyme inhibitors |
| GB201004179D0 (en) | 2010-03-12 | 2010-04-28 | Pulmagen Therapeutics Inflamma | Enzyme inhibitors |
| KR20140060513A (ko) | 2011-09-14 | 2014-05-20 | 키에시 파르마슈티시 엣스. 피. 에이. | 인체 호중구 엘라스타제 억제제인 테트라히드로트리아졸로피리미딘 유도체 |
| WO2013084199A1 (en) | 2011-12-07 | 2013-06-13 | Universidade De Lisboa | Boron heterocycles as new inhibitors of human neutrophil elastase |
| CA2878792A1 (en) | 2012-07-12 | 2014-01-16 | Chiesi Farmaceutici S.P.A. | Inhibition of enzymes |
| US20140057926A1 (en) | 2012-08-23 | 2014-02-27 | Boehringer Ingelheim International Gmbh | Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity |
| US9102624B2 (en) | 2012-08-23 | 2015-08-11 | Boehringer Ingelheim International Gmbh | Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity |
| US20140057920A1 (en) | 2012-08-23 | 2014-02-27 | Boehringer Ingelheim International Gmbh | Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity |
| US20140221335A1 (en) | 2013-02-06 | 2014-08-07 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
| US9115093B2 (en) | 2013-03-04 | 2015-08-25 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
| EP3083626B1 (en) | 2013-12-16 | 2017-10-25 | CHIESI FARMACEUTICI S.p.A. | Tetrahydrotriazolopyrimidine derivatives as human neutrophil elastase inhibitors |
| EA034910B1 (ru) | 2013-12-27 | 2020-04-06 | Полифор Аг | Бета-шпилечные пептидомиметики в качестве селективных ингибиторов эластазы |
| SI3087094T1 (sl) | 2013-12-27 | 2022-11-30 | Spexis Ag | BETA-lasnični peptidomimetiki kot selektivni zaviralci elastaze |
| US9221807B2 (en) | 2014-02-21 | 2015-12-29 | Boehringer Ingelheim International Gmbh | Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity |
| WO2015200349A2 (en) * | 2014-06-24 | 2015-12-30 | The California Institute For Biomedical Research | Elastase inhibitors |
| US9475779B2 (en) | 2014-07-31 | 2016-10-25 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
| US9290457B2 (en) | 2014-07-31 | 2016-03-22 | Boehringer Ingelheim International Gmbh | Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
| US9657015B2 (en) * | 2014-07-31 | 2017-05-23 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
| US9458113B2 (en) | 2014-07-31 | 2016-10-04 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
| US9440930B2 (en) | 2014-07-31 | 2016-09-13 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
| EP3193910A1 (en) | 2014-08-05 | 2017-07-26 | Réunion Therapeutics B.V. | Mutants of leech derived neutrophil elastase inhibitors and uses thereof |
| WO2016050835A2 (en) | 2014-10-02 | 2016-04-07 | Ruprecht-Karls-Universität Heidelberg | Selective inhibitors of neutrophil elastase for treating neuropathic pain and chronic pain states harbouring a neuropathic component |
| US9890169B2 (en) | 2015-12-14 | 2018-02-13 | Chiesi Farmaceutici S.P.A. | Triazolinone compounds as HNE inhibitors |
| UA123109C2 (uk) | 2016-05-31 | 2021-02-17 | К'Єзі Фармачеутічі С.П.А. | Сполуки імідазолону як інгібітори нейтрофіл-еластази людини |
| KR20220079527A (ko) * | 2019-09-17 | 2022-06-13 | 메레오 바이오파마 4 리미티드 | 이식편 거부반응, 폐쇄성 세기관지염 증후군 및 이식편 대 숙주병의 치료에 사용하기 위한 알베레스타트 |
| WO2021178448A1 (en) * | 2020-03-02 | 2021-09-10 | Motor Life Sciences, Llc | Compositions and methods for diagnosing, preventing, and treating amyotrophic lateral sclerosis in patients with hypofunctional anti-trypsin activity |
-
2021
- 2021-03-16 IL IL297211A patent/IL297211A/en unknown
- 2021-03-16 US US17/995,909 patent/US20230190723A1/en active Pending
- 2021-03-16 WO PCT/GB2021/050658 patent/WO2021209740A1/en active Application Filing
- 2021-03-16 HU HUE21714345A patent/HUE064089T2/hu unknown
- 2021-03-16 HR HRP20231065TT patent/HRP20231065T1/hr unknown
- 2021-03-16 US US17/995,908 patent/US20230218596A1/en active Pending
- 2021-03-16 JP JP2022562608A patent/JP2023522010A/ja active Pending
- 2021-03-16 EP EP21714345.2A patent/EP4106757B1/en active Active
- 2021-03-16 EP EP23187058.5A patent/EP4252850A3/en active Pending
- 2021-03-16 LT LTEPPCT/GB2021/050653T patent/LT4106757T/lt unknown
- 2021-03-16 MX MX2022012942A patent/MX2022012942A/es unknown
- 2021-03-16 PL PL21714345.2T patent/PL4106757T3/pl unknown
- 2021-03-16 DK DK21714345.2T patent/DK4106757T3/da active
- 2021-03-16 ES ES21714345T patent/ES2962498T3/es active Active
- 2021-03-16 FI FIEP21714345.2T patent/FI4106757T3/fi active
- 2021-03-16 PT PT217143452T patent/PT4106757T/pt unknown
- 2021-03-16 WO PCT/GB2021/050653 patent/WO2021209739A1/en unknown
- 2021-03-16 SI SI202130071T patent/SI4106757T1/sl unknown
- 2021-03-16 AU AU2021256835A patent/AU2021256835A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023522010A (ja) | 2023-05-26 |
| EP4106757B1 (en) | 2023-08-23 |
| EP4252850A2 (en) | 2023-10-04 |
| US20230190723A1 (en) | 2023-06-22 |
| DK4106757T3 (da) | 2023-10-23 |
| WO2021209740A1 (en) | 2021-10-21 |
| HUE064089T2 (hu) | 2024-02-28 |
| EP4106757A1 (en) | 2022-12-28 |
| AU2021256835A1 (en) | 2022-10-13 |
| MX2022012942A (es) | 2023-01-11 |
| EP4252850A3 (en) | 2023-11-15 |
| FI4106757T3 (fi) | 2023-10-23 |
| SI4106757T1 (sl) | 2023-11-30 |
| IL297211A (en) | 2022-12-01 |
| US20230218596A1 (en) | 2023-07-13 |
| ES2962498T3 (es) | 2024-03-19 |
| PT4106757T (pt) | 2023-11-17 |
| LT4106757T (lt) | 2023-11-10 |
| WO2021209739A1 (en) | 2021-10-21 |
| PL4106757T3 (pl) | 2024-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018111728A5 (hr) | ||
| HRP20230272T1 (hr) | Postupci za liječenje cistične fibroze | |
| JP5902628B2 (ja) | 相乗的抗ウイルス組成物及びその使用 | |
| NZ600790A (en) | Combination therapy for copd | |
| HRP20100014T1 (hr) | Uporaba il-23 i il-17 antagonista u liječenju autoimune očne upalne bolesti | |
| JP2016513097A5 (hr) | ||
| CA2474479A1 (en) | Composition for inhalation | |
| RS52940B (en) | PHARMACEUTICAL FORMULATIONS OF SOLUTION FOR MEASURED DOSES OF PRESSURE INHALATORS | |
| AR042578A1 (es) | Inhibidores de la sintesis de mucina | |
| ATE330589T1 (de) | Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege | |
| HRP20140550T1 (hr) | Aerosolna formulacija za copd | |
| WO2006029036A3 (en) | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis | |
| WO2007110871A3 (en) | Methods and composition for treating sore throat | |
| HRP20121033T1 (hr) | Praškasta formulacija za valganciklovir | |
| JP2019528316A5 (hr) | ||
| JPH05163139A (ja) | 抗動脈硬化剤 | |
| KR20070034642A (ko) | 맥관형성 수반 질환의 치료를 위한 배합물 | |
| HRP20192246T1 (hr) | Marker za poremećaje kisele sfingomijelinaze i njegova uporaba | |
| HRP20192189T1 (hr) | Doziranja i terapijske primjene l-4-klorokinurenina | |
| HRP20160211T1 (hr) | Liječenje multiple skleroze (ms) s campath-1h | |
| HRP20200142T1 (hr) | Postupci i sastavi za liječenje depresije uporabom ciklobenzaprina | |
| TR201908270T4 (tr) | Steroidlerin veya antihistaminiklerin yan etkilerini azaltmak için osmolit. | |
| JP2019532112A5 (ja) | 結節性痒疹を治療するための抗掻痒剤 | |
| HRP20231065T1 (hr) | Postupci koji uključuju alvelestat inhibitor neutrofilne elastaze za liječenje respiratorne bolesti posredovane putem nedostatka alfa-1 antitripsina | |
| Meltzer et al. | New intranasal formulations for the treatment of allergic rhinitis. |